Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

Puig-Domingo, M.; Soto, Alfonso; Venegas, Eva; Vilchez, Ricardo; Blanco, Concepción; Cordido, Fernando; Lucas, T.; Marazuela, Mónica; Casany, Rosa; Cuatrecasas, Guillem; Fajardo, Carmen; Gálvez, María A.; Maraver, Silvia; Martín, Tomás; Romero, Enrique; Paja, Miguel; Picó, Antonio; Bernabéu, Ignacio; Resmini, Eugenia

doi:10.1016/j.endoen.2016.09.006

Cited by 2 publications

(2 citation statements)

References 39 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the 2018 consensus statement on acromegaly therapeutic outcomes recommends that an increase of dose and/or dose frequency of first-generation somatostatin analog or the addition of cabergoline may be considered in patients having a partial response [6]. Other options for treatment optimization include switching to pasireotide LAR or pegvisomant or combination with pegvisomant [6,51]. In our study, physicians opted for combination of lanreotide autogel with dopamine agonists in 17.1 % and with pegvisomant in 6.6 % of patients.…”

Section: Discussionmentioning

confidence: 99%

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland

Störmann

Schopohl

Bullmann

et al. 2020

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Background Evidence from controlled trials has shown that lanreotide autogel is effective in achieving biochemical and symptom control in patients with acromegaly. However, it is important to better understand the real-world patient population receiving lanreotide autogel treatment. Methods In this non-interventional study the long-term treatment response to lanreotide autogel in adult patients with acromegaly from office-based centers or clinics in Germany, Austria and Switzerland was studied. Assessments included growth hormone and insulin-like growth factor-I levels, symptoms, quality of life, lanreotide plasma levels and tumor somatostatin receptor subtype expression. The primary endpoint was achievement of full biochemical control, defined as growth hormone ≤2.5 µg/L and insulin-like growth factor I normalization at month 12. Results 76 patients were enrolled from 21 sites. 7/51 (13.7%) patients of the efficacy population had full biochemical control at baseline, 15/33 (45.5%) at month 12 and 10/26 (38.5%) at month 24 of treatment. At 12 months of treatment higher rates of biochemical control were observed in the following subgroups: older patients (>53 years [median]), females, treatment-naïve patients, and patients with a time since diagnosis of longer than 1.4 years (median). No clinically relevant differences in acromegaly symptoms or quality of life scores were observed. Median fasting blood glucose and glycated hemoglobin levels remained unchanged throughout the study. No new safety signals were observed. Overall tolerability of treatment with lanreotide autogel was judged by 80.8% of the enrolled patients at month 12 as ‘very good’ or ‘good’. Conclusion Treatment with lanreotide autogel in a real-world setting showed long-term effectiveness and good tolerability in patients with acromegaly.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland

Störmann

Schopohl

Bullmann

et al. 2020

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…From the available data in the literature, combination treatment of CAB with first-generation SRLs seems to result in higher rates of disease control than monotherapy, [10][11][12][13][14][15][16][33][34][35][36][37] which is an interesting option in patients who are not totally controlled with SRL. We have previously reviewed the literature and found a control rate of 34%.…”

Section: Discussionmentioning

confidence: 99%

Treatment escape reduces the effectiveness of cabergoline during long‐term treatment of acromegaly in monotherapy or in association with first‐generation somatostatin receptor ligands

Kasuki

Dalmolin

Wildemberg

2018

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

Abstract: Uso de lanreotida en combinación con cabergolina o pegvisomant en la práctica clínica en pacientes con acromegalia: el estudio ACROCOMB

Cited by 2 publications

References 39 publications

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland

Treatment escape reduces the effectiveness of cabergoline during long‐term treatment of acromegaly in monotherapy or in association with first‐generation somatostatin receptor ligands

Contact Info

Product

Resources

About